Search Results - "Gonzalez De Castro, D."

Early circulating tumour DNA kinetics measured by ultra-deep next-generation sequencing during radical radiotherapy for non-small cell lung cancer: a feasibility study by Walls, G M, McConnell, L, McAleese, J, Murray, P, Lynch, T B, Savage, K, Hanna, G G, de Castro, D Gonzalez

“…The evaluation of circulating tumour DNA (ctDNA) from clinical blood samples, liquid biopsy, offers several diagnostic advantages compared with traditional…”
Get full text

Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial by Strefford, J C, Kadalayil, L, Forster, J, Rose-Zerilli, M J J, Parker, A, Lin, T T, Heppel, N, Norris, K, Gardiner, A, Davies, Z, Gonzalez de Castro, D, Else, M, Steele, A J, Parker, H, Stankovic, T, Pepper, C, Fegan, C, Baird, D, Collins, A, Catovsky, D, Oscier, D G

Get full text

A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens by Gonzalez de Castro, D, Angulo, B, Gomez, B, Mair, D, Martinez, R, Suarez-Gauthier, A, Shieh, F, Velez, M, Brophy, V H, Lawrence, H J, Lopez-Rios, F

“…Background: KRAS mutation testing is required to select patients with metastatic colorectal cancer (CRC) to receive anti-epidermal growth factor receptor…”
Get full text

Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns by Moore, A S, Faisal, A, de Castro, D Gonzalez, Bavetsias, V, Sun, C, Atrash, B, Valenti, M, de Haven Brandon, A, Avery, S, Mair, D, Mirabella, F, Swansbury, J, Pearson, A D J, Workman, P, Blagg, J, Raynaud, F I, Eccles, S A, Linardopoulos, S

“…Acquired resistance to selective FLT3 inhibitors is an emerging clinical problem in the treatment of FLT3 -ITD + acute myeloid leukaemia (AML). The paucity of…”
Get full text

Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance by Gonzalez de Castro, D, Clarke, P A, Al-Lazikani, B, Workman, P

“…The progressive elucidation of the molecular pathogenesis of cancer has fueled the rational development of targeted drugs for patient populations stratified by…”
Get full text

Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice by Moorcraft, S.Y., Gonzalez de Castro, D., Cunningham, D., Jones, T., Walker, B.A., Peckitt, C., Yuan, L.C., Frampton, M., Begum, R., Eltahir, Z., Wotherspoon, A., Teixeira Mendes, L.S., Hulkki Wilson, S., Gillbanks, A., Baratelli, C., Fotiadis, N., Patel, A., Braconi, C., Valeri, N., Gerlinger, M., Rao, S., Watkins, D., Chau, I., Starling, N.

“…Targeted capture sequencing can potentially facilitate precision medicine, but the feasibility of this approach in gastrointestinal (GI) malignancies is…”
Get full text

HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab by Sclafani, F., Roy, A., Cunningham, D., Wotherspoon, A., Peckitt, C., Gonzalez de Castro, D., Tabernero, J., Glimelius, B., Cervantes, A., Eltahir, Z., Oates, J., Chau, I.

“…HER2 is an established therapeutic target in breast and gastric cancers. The role of HER2 in rectal cancer is unclear, as conflicting data on the prevalence of…”
Get full text

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial by Sclafani, F., Chau, I., Cunningham, D., Peckitt, C., Lampis, A., Hahne, J.C., Braconi, C., Tabernero, J., Glimelius, B., Cervantes, A., Begum, R., Gonzalez De Castro, D., Hulkki Wilson, S., Eltahir, Z., Wotherspoon, A., Tait, D., Brown, G., Oates, J., Valeri, N.

“…Lethal-7 (let-7) is a tumour suppressor miRNA which acts by down-regulating several oncogenes including KRAS. A single-nucleotide polymorphism (rs61764370, T >…”
Get full text

Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials by Okines, A.F.C, Gonzalez de Castro, D, Cunningham, D, Chau, I, Langley, R.E, Thompson, L.C, Stenning, S.P, Saffery, C, Barbachano, Y, Coxon, F, Middleton, G, Ferry, D, Crosby, T, Madhusudan, S, Wadsley, J, Waters, J, Hall, M, Swinson, D, Robinson, A, Smith, D, Reis-Filho, J.S, Waddell, T.S, Puckey, L, Hulkki Wilson, S, Eltahir, Z, Band, M, Wotherspoon, A

“…Abstract Background REAL3 (Randomised ECF for Advanced or Locally advanced oesophagogastric cancer 3) was a phase II/III trial designed to evaluate the…”
Get full text

CELL‐FREE DNA KINETICS DECIPHER POTENTIAL MECHANISMS OF ACTION OF IBRUTINIB COMBINATION THERAPY IN MANTLE CELL LYMPHOMA (MCL) by Khouja, M., Genuardi, E., Ferrero, S., Alessandria, B., Verhagen, O. J., Homburg, C., Velden, V. H., Gameiro, P., Sanz, R. García, Herrera, A. Medina, Fronkova, E., Brüggemann, M., Dreyling, M., Hoster, E., Ladetto, M., Langerak, A. W., Darzentas, N., Pal, K., Stewart, P. J., Gonzalez de Castro, D., Pott, C.

Get full text

16 EGFR mutational analysis for adenocarcinoma of the lung; outcome by mutation since the introduction of routine molecular testing in one cancer network by Okines, A.F.C, Brulinski, P, Gonzalez de Castro, D, Shah, R

Get full text

83: A review of the first 10 months of screening selected patients for the ALK translocation using immunohistochemistry, and their subsequent treatment by Viola, P, Popat, S, Khan, O, Moule, R, Polychronis, A, Stokoe, J, Dickson, J, Montero Fernandez, A, Amat Villegas, I, Yancheva, S, Gonzalez de Castro, D, Nicholson, A.G

Get full text

A-202 Validation Of Next Generation Sequencing Using EuroClonality-NDC Panel In Primary Cutaneous Lymphomas and comparison with Traditional PCR Techniques by Hatzakis, A., Pugh, M., Hock, Y.L., Rooke, B., Murray, D., Alluri, U., Shah, F., Kashipaz, R. Amel, Vydianath, B., de Castro, D. Gonzalez, Taniere, P., Scarisbrick, J.

Get full text

Clinical validation of a novel assay for the detection of diagnostic alterations in sarcomas by Mc Connell, L., Houghton, O., Catherwood, M., Gazdova, J., Stewart, P., Oniscu, A., Groenen, P., Kroeze, L., Taniere, P., Flanagan, A., Stobl, A., Salto-Tellez, M., De Castro, D Gonzalez

Get full text

1717P - Clinical validation of a novel assay for the detection of diagnostic alterations in sarcomas by Mc Connell, L., Houghton, O., Catherwood, M., Gazdova, J., Stewart, P., Oniscu, A., Groenen, P., Kroeze, L., Taniere, P., Flanagan, A., Stobl, A., Salto-Tellez, M., De Castro, D Gonzalez

“…Sarcoma is a rare disease affecting both bone and connective tissue and with over 100 pathologic entities, diagnosis can be difficult. Approximately one third…”
Get full text

1717PClinical validation of a novel assay for the detection of diagnostic alterations in sarcomas by Mc Connell, L, Houghton, O, Catherwood, M, Gazdova, J, Stewart, P, Oniscu, A, Groenen, P, Kroeze, L, Taniere, P, Flanagan, A, Stobl, A, Salto-Tellez, M, De Castro, D Gonzalez

“…Abstract Background Sarcoma is a rare disease affecting both bone and connective tissue and with over 100 pathologic entities, diagnosis can be difficult…”
Get full text

Abstract P1-09-10: Molecular and genetic characterisation of contralateral breast cancers in Northern Ireland: Opportunities for personalised surgery by McIlmunn, CG, Bannon, FJ, Fitzpatrick, D, Ervine, A, Boyd, C, Cameron, I, Harita, T, James, J, Gonzalez de Castro, D, Savage, KI, McIntosh, SA

“…Abstract Contralateral breast cancer (CBC) incidence is reported as 0.4-0.7% per year, equating to an approximate 10-15% 20 year risk after primary cancer…”
Get full text

Diagnostic EGFR testing with ctDNA versus tumour in patients with advanced non-small cell lung cancer (NSCLC): The Royal Marsden experience by Kumar, R., Walder, D.P., Bhosle, J., Yap, T.A., O'Brien, M.E.R., Popat, S., Thompson, L., Macmahon, S., Palma, J., Gonzalez de Castro, D.

Get full text

FCγRIIa and FCγRIIIa single nucleotide polymorphisms (SNPs) and cetuximab benefit in the EXCITE trial by Sclafani, F., Gollins, S., Cunningham, D., Hulkki Wilson, S., Kouvelakis, K., Lopes, A., West, N., Quirke, P., Begum, R., Valeri, N., Beare, S., Hughes, L., Gonzalez De Castro, D., Chau, I.

Get full text

200PA BLOOD BASED EGFR MUTATION ANALYSIS IN CIRCULATING PLASMA DNA FOR PREDICTION OF PRIMARY TUMOUR MUTATIONS IN LUNG CANCER by Freydin, M., Freydina, D.V., Chudasama, D., Leung, M., Popat, S., Gonzalez-De-Castro, D., Rice, A., Fernandez, A. Montero, Nicholson, A.G., Lim, E.

“…Abstract Aim: Biopsy of the primary tumour for predictive testing is not always convenient nor possible and may incur both delays and complications. In a move…”
Get full text